Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aradigm Corp. (NASDAQ: ARDM).

Full DD Report for ARDM

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARDM)

Aradigm Announces First Quarter 2018 Financial Results
Aradigm Corporation (NASDAQ: ARDM) (the “Company”) today announced financial results for the first quarter and three months ended March 31, 2018. First Quarter 2018 Financial Results The Company recorded $1.5 million in revenue in the first quarter of 2018 compare...
Source: Business Wire
Date: May, 15 2018 08:00
New Research Coverage Highlights Aradigm, Ultra Petroleum, TRI Pointe Group, Finisar, Tesla, and The Progressive - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aradigm Corporation (NASDAQ:ARDM), Ultra Petroleum Corp. (NASDAQ:UPL), T...
Source: GlobeNewswire
Date: April, 16 2018 08:20
Wired News - EMA Completed Validation of MAA for Aradigm's Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you want access to this report all you need to do is sign up now by clicking the foll...
Source: ACCESSWIRE IA
Date: April, 09 2018 07:20
Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study
A nalysis focus: Conatus Conatus (NASDAQ: CNAT ) shares tumbled after the company announced top-line results from a phase 2b POLT-HCV-SVR clinical study. The phase 2b study was evaluating CNAT’s lead product candidate emricasan, a first-in-class pan-caspase protease inhibitor ...
Source: SeekingAlpha
Date: April, 06 2018 11:18
EMA accepts Aradigm's marketing application for Linhaliq for certain lung infections; shares ahead 9%
The European Medicines Agency (EMA) has accepted for review Aradigm's ( ARDM +8.6% ) marketing application seeking approval for Linhaliq (ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aerugino...
Source: SeekingAlpha
Date: April, 05 2018 10:05
Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission
Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung...
Source: Business Wire
Date: April, 05 2018 08:00
Aradigm reports Q4 results
Aradigm (NASDAQ: ARDM ): Q4 EPS of -$0.28 More news on: Aradigm Corp., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 23 2018 08:02
Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results
Subsequent Highlights Cash and cash equivalents of $7.1 million expected to be sufficient to fund operations for Q1 2018; temporary measures implemented to preserve cash resources Focus on European Approval for Linhaliq – Marketing Authorization Application for EU filed ...
Source: Business Wire
Date: March, 23 2018 08:00
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm
LOS ANGELES, CA / ACCESSWIRE / March 12, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aradigm Corporation ("Aradigm" or the "Company") (NASDAQ: ARDM ) for violations of §§10(b) and 20(a) of the ...
Source: ACCESSWIRE IA
Date: March, 12 2018 12:35
Glancy Prongay & Murray LLP Reminds Investors of the March 12, 2018 Deadline in the Class Action Lawsuit Against Aradigm Corporation
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 12, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Aradigm Corporation (“Aradigm” or the “Company”) (NASDAQ...
Source: Business Wire
Date: March, 12 2018 10:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-171.431.421.45991.386910,798
2017-06-201.541.521.551.4612,440
2017-06-191.541.511.57751.4222,182
2017-06-161.491.521.551.43017,123
2017-06-151.481.501.501.449,016

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-209321,13282.3322Short
2018-08-173002,30713.0039Cover
2018-08-163,7296,65156.0668Short
2018-08-156,72311,15260.2852Short
2018-08-14123,1270.3838Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARDM.


About Aradigm Corp. (NASDAQ: ARDM)

Logo for Aradigm Corp. (NASDAQ: ARDM)

Not available

 

Contact Information

 

 

Current Management

  • Igor Gonda / President, CEO
  • Nancy Pecota / CFO
  • Rita mateo / IR

Current Share Structure

  • Market Cap: $22,300,194 - 05/14/2018
  • Issue and Outstanding: 15,170,200 - 03/12/2018

 


Recent Filings from (NASDAQ: ARDM)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 17 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 15 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018

 

 


Daily Technical Chart for (NASDAQ: ARDM)

Daily Technical Chart for (NASDAQ: ARDM)


Stay tuned for daily updates and more on (NASDAQ: ARDM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ARDM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARDM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ARDM and does not buy, sell, or trade any shares of ARDM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/